Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening
This study has been completed.
Sponsors and Collaborators: M.D. Anderson Cancer Center
University of Michigan
Information provided by: M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier: NCT00037843
  Purpose

This is a clinical research study using I-131 Iodocholesterol which is an experimental radioactive chemical that when injected into the vein, is picked up in the adrenal glands and permits visualization with gamma imaging devices. These images are used in diagnosing a variety of adrenal abnormalities.Prior to the injection of I-131 Iodocholesterol, the patient will receive perchlorate capsules to block any uptake of I-131 by the thyroid gland if this is deemed important. The patient will continue to take these capsules throughout the period of imaging, which may last up to 1 week. The injection of I-131 Iodocholesterol will be given into a vein and the patient will return for images on at least 1 and possibly 2 occasions between 3-7 days after injection. If the case requires it, the patient may also be given a steroid in tablet form, dexamethasone, to take orally prior to and after the injection to suppress normal adrenal function so that the abnormal tissues can be more easily detected.


Condition Intervention Phase
Adrenal Gland Diseases
Adrenal Gland Neoplasms
Drug: I-131 Iodocholesterol
Phase III

MedlinePlus related topics: Cancer
Drug Information available for: Iodine Cadexomer iodine Sodium iodide I 131 Epinephrine Epinephrine bitartrate
U.S. FDA Resources
Study Type: Interventional
Study Design: Diagnostic, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Official Title: Iodine I-131 Iodocholesterol, Its Use in Adrenal Screening

Further study details as provided by M.D. Anderson Cancer Center:

Estimated Enrollment: 125
Study Start Date: December 1988
Study Completion Date: August 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Adults with suspected adrenal disease, such as adrenal adenoma, carcinoma, hyperplasia, or Addison's Disease.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00037843

Locations
United States, Texas
University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States, 77030
Sponsors and Collaborators
M.D. Anderson Cancer Center
University of Michigan
Investigators
Principal Investigator: Donald A. Podoloff, MD U.T. M.D. Anderson Cancer Center
  More Information

Study ID Numbers: NUM88-001
Study First Received: May 23, 2002
Last Updated: October 8, 2007
ClinicalTrials.gov Identifier: NCT00037843  
Health Authority: United States: Food and Drug Administration

Keywords provided by M.D. Anderson Cancer Center:
adrenal diseases

Study placed in the following topic categories:
Adrenal Gland Neoplasms
Iodine
Endocrine System Diseases
Adrenal Gland Diseases
Endocrinopathy
Epinephrine
Endocrine Gland Neoplasms

Additional relevant MeSH terms:
Neoplasms
Neoplasms by Site

ClinicalTrials.gov processed this record on January 16, 2009